vaccine

Moderna's mRNA flu vaccine mFLUSIVA received FDA approval for adults over 50, marking the first mRNA-based flu shot. However, uncertainty remains due to the CDC advisory panel being defunct amid litigation, affecting coverage recommendations.

Moderna announced FDA approval of mFLUSIVA (mRNA-1010), a seasonal influenza vaccine for adults 50 and older, following unanimous advisory committee recommendations.

The article describes how a promising Ebola vaccine developed by Thomas Geisbert has remained unused for 15 years due to lack of funding and commercial interest, despite its potential to combat the current Bundibugyo outbreak in Central and East Africa.

A study of over 1 million VA patients found that the updated 2024–2025 COVID-19 vaccine still provides significant protection against cardiovascular events like heart attack and stroke, especially in people over 75 and those with underlying conditions.